A5059294353- Diabetes Management and Research
- Diabetes Treatment and Management
- Diabetes Management and Education
- Diet and metabolism studies
- Pharmacology and Obesity Treatment
- Metabolism, Diabetes, and Cancer
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Medication Adherence and Compliance
- Chronic Disease Management Strategies
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Heart Rate Variability and Autonomic Control
- Diabetes and associated disorders
- Sexual Differentiation and Disorders
- Health Policy Implementation Science
- Lung Cancer Treatments and Mutations
- Nutrition and Health in Aging
- Lung Cancer Research Studies
- Pancreatic function and diabetes
- Cardiovascular Syncope and Autonomic Disorders
- Public Health and Social Inequalities
- School Health and Nursing Education
- Frailty in Older Adults
- Eating Disorders and Behaviors
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- HER2/EGFR in Cancer Research
Eli Lilly (United States)
2014-2025
Indianapolis Zoo
2016-2024
Arlington Free Clinic
2023
AID Atlanta
2019
Renton Technical College
2019
Accadis Hochschule Bad Homburg
2018
Hershey (United States)
2018
Adelphi Group (United Kingdom)
2015
Senju Pharmaceutical (United States)
2015
University of Arizona
2015
Short stature and ovarian failure are characteristic features of Turner's syndrome. Although recombinant human growth hormone is commonly used to treat the short associated with this syndrome, a randomized, placebo-controlled trial needed document whether such treatment increases adult height. Furthermore, it not known childhood estrogen replacement combined therapy provides additional benefit. We examined independent effects early, ultra-low-dose on height in girls
To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus in adults with type 1 diabetes a 26-week, treat-to-target, phase 3 trial.
Abstract Aims We assessed changes in body composition following tirzepatide treatment a substudy of participants with obesity or overweight from the SURMOUNT‐1 trial, overall and post hoc clinically relevant subgroups. Materials Methods Substudy ( n = 160 2539 SURMOUNT‐1) underwent dual‐energy X‐ray absorptiometry (DXA) at baseline Week 72. Body parameters were evaluated by analysis covariance, logistic regression Fisher's exact test. Post subgroup analyses conducted sex (female male), age...
Background: The short stature homeobox-containing gene, SHOX, located on the distal ends of X and Y chromosomes, encodes a homeodomain transcription factor responsible for significant proportion long-bone growth. Patients with mutations or deletions including those Turner syndrome (TS) who are haploinsufficient have variable degrees growth impairment, without spectrum skeletal anomalies consistent dyschondrosteosis.
Abstract Aims To assess treatment satisfaction and weight‐related quality of life (QOL) in subjects with Type 2 diabetes treated exenatide once weekly (QW) or twice daily (BID). Methods In this 52‐week randomized, multi‐centre, open‐label study, 295 managed diet exercise and/or oral glucose‐lowering medications received either QW BID during weeks 1–30; thereafter, receiving were switched to QW, 258 total 30–52. Diabetes Treatment Satisfaction Questionnaire—status (DTSQ‐s) Impact Weight on...
BACKGROUND Vascular endothelial growth factor (VEGF)–mediated angiogenesis plays an important role in non–small cell lung cancer (NSCLC). Ramucirumab is a human immunoglobulin G1 monoclonal antibody that inhibits VEGF receptor 2. This phase 2 study investigated ramucirumab combination with first‐line pemetrexed and platinum chemotherapy advanced/metastatic NSCLC. METHODS Eligible stage IV nonsquamous NSCLC patients no prior for metastatic disease were randomized 1:1 to carboplatin (or...
Aim: To test the hypothesis that glycaemic control with exenatide added to thiazolidinediones (TZDs) or without metformin was superior placebo. Methods: A 26‐week, multi‐country (Canada, Mexico, Romania, South Africa and USA), randomized, double‐blind, placebo‐controlled study compared twice‐daily vs. placebo in 165 subjects suboptimally controlled TZDs [HbA 1c 8.2% (s.d. 0.9), fasting serum glucose 9.1 (2.6) mmol/l, body weight 93.9 (17.8) kg, diabetes duration 6.4 (4.3) years]. After a...
Abstract Aims This analysis evaluated whether gastrointestinal (GI) adverse events (AEs) including nausea, vomiting, diarrhoea (N/V/D) and dyspepsia were associated with weight reduction tirzepatide across the SURMOUNT‐1 to ‐4 trials. Materials Methods global Phase 3 clinical trials evaluating safety efficacy of among participants obesity or overweight without type 2 diabetes (T2D). Participants randomly assigned receive once weekly subcutaneous placebo. post hoc investigated change at...
Summary The rate of weight reduction during obesity treatment declines over time and eventually reaches a plateau. We investigated factors associated with to plateau (TTWP) in tirzepatide‐treated participants or overweight post‐hoc analysis SURMOUNT‐1 SURMOUNT‐4 trials. Participants adherent tirzepatide achieving ≥5% loss by primary endpoint (week 72 SURMOUNT‐1; week 88 SURMOUNT‐4) were included. Weight was defined as change <5% 12‐week interval all subsequent intervals. TTWP from...
In SURMOUNT-2, a phase 3, randomized clinical trial, tirzepatide treatment resulted in clinically meaningful reduction bodyweight among people with obesity or overweight and T2D. The current analysis evaluated the effects of on self-reported health-related quality life (HRQoL) outcomes SURMOUNT-2 participants. participants were randomly assigned (1:1:1) to receive either 10 mg (n = 312), 15 311), placebo 315) for 72 weeks as an adjunct diet exercise. Self-reported HRQoL was assessed terms...
Patients with mutations or deletions of the Short Stature Homeobox-containing(SHOX) gene have variable degrees growth impairment, without mesomelic skeletal dysplasia. If untreated, short patients SHOX deficiency remain in adulthood. Growth hormone (GH) treatment improves short-term linear growth; however, there are no data on GH effects final height.In a retrospective study, we assessed relative height gain (n = 14; 12 females) and Turner syndrome (TS) 158). were included if they fulfilled...
To assess basal insulin persistence, associated factors, and economic outcomes for insulin-naïve people with type 2 diabetes mellitus (T2DM) in the US.People aged ≥18 years diagnosed T2DM initiating between April 2006 March 2012 (index date), no prior use, continuous insurance coverage 6 months before (baseline) 24 after index date (follow-up period) were selected using de-identified administrative claims data US. Based on whether there ≥30 day gaps use first year post-index, patients...
Background: This study evaluated glucose control by continuous monitoring (CGM) during treatment with ultra-rapid lispro (URLi) or used in combination insulin glargine degludec adults type 1 diabetes a substudy of the PRONTO-T1D study. Methods: Ambulatory profiles were 269 patients from assigned to double-blind URLi (n = 97) 99) given 0-2 min before start meal (mealtime), open-label 73) 20 after (postmeal URLi). Blinded CGM was for up 14 days baseline and 26-week primary endpoint. The...
Abstract Aims The SURMOUNT‐1 trial investigated effects of tirzepatide, a glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist, on body weight in participants with obesity or overweight. This analysis evaluated changes patient‐reported outcomes (PROs) assessing physical function, psychosocial well‐being, overall health aspects participants' health‐related quality life (HRQoL) SURMOUNT‐1. Methods PRO instruments included the Impact Weight Quality Life‐Lite...
To identify actions of healthcare professionals (HCPs) that facilitate the transition to insulin therapy (IT) in type 2 diabetes (T2D) adults.Included were T2Ds seven countries (n = 594) who reported initial IT reluctance but eventually began IT. An online survey included 38 possible HCP actions: indicated which may have occurred and their helpfulness. Also delays start after recommendation any period discontinuation.Exploratory factor analysis yielded five factors: "Explained Insulin...
People with T2DM who initiate basal insulin therapy often stop temporarily or permanently soon after initiation. This study analyzes the reasons for and correlates of stopping restarting among people T2DM.An online survey was completed by 942 insulin-naïve adults self-reported from Brazil, France, Germany, Japan, Spain, UK, US. Respondents had initiated within 3-24 months before participation met criteria one three persistence groups: continuers no gaps ≥7 days in treatment; interrupters at...
Objective To understand participant perceptions about insulin and identify key behaviors of healthcare professionals (HCPs) that motivated initially reluctant adults from seven countries (n=40) who had type 2 diabetes (T2D) to start treatment. Research design methods Telephone interviews were conducted with a subset participants an international investigation T2D (EMOTION). Questions related to: (a) participants’ thoughts before after initiation; (b) reasons behind responses on the survey...
People with type 2 diabetes mellitus (T2DM) often interrupt basal insulin treatment soon after initiation. This study aimed to describe the experiences during and initiation among people T2DM different persistence patterns.Adults from France, Germany, Spain, UK, US, Brazil, Japan were identified consumer panels for an online survey. Respondents who initiated 3-24 months prior survey date categorized as continuers (no gaps of ≥7 days in treatment); interrupters (first gap within 6 restarted...
The objective of this study was to assess basal insulin persistence, associated factors, and economic outcomes for insulin-naïve people with type 2 diabetes mellitus (T2DM) in Japan. People aged at least 18 years T2DM first claim between May 2006 April 2013 (index date), no use before index date, continuous insurance coverage 6 months (baseline) 12 after date were selected from the Japan Medical Center Database. On basis whether there 30-day gaps treatment, patients classified as continuers...
Abstract Disclosure: T.M. Gibble: Employee; Self; Employment and stockholder, Eli Lilly Company. D. Cao: M. Murphy: I. Jouravskaya: B. Liao: Background: Tirzepatide is approved in the U.S. for treatment of type 2 diabetes (T2D) obesity. In phase 3 SURMOUNT-4 trial with randomized withdrawal tirzepatide maximum tolerated dose (MTD) after first 36 weeks, continuing 88 weeks led to a mean weight reduction 25.3% from baseline compared 9.9% those who switched placebo (PBO).1 This analysis...
Introduction & Objective: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved in the US for treatment of type 2 diabetes obesity. In phase 3, randomized, double-blind, placebo (PBO)-controlled SURMOUNT-2 (NCT04657003) trial, tirzepatide-treated adults showed substantial weight reduction vs PBO. This post-hoc analysis assessed association between achieving targets improvements health-related quality life (HRQoL). Methods:...